Invanz is a brand name of ertapenem, approved by the FDA in the following formulation(s):
INVANZ (ertapenem sodium - injectable; intramuscular, iv (infusion))
Manufacturer: MERCK
Approval date: November 21, 2001
Strength(s): EQ 1GM BASE/VIAL [RLD]
Has a generic version of Invanz been approved?
No. There is currently no therapeutically equivalent version of Invanz available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invanz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Antibiotic compounds
Patent 5,478,820
Issued: December 26, 1995
Inventor(s): Betts; Michael J. & Davies; Gareth M. & Swain; Michael L.
Assignee(s): Zeneca Ltd.
The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(N-C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O).sub.n -- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the --NR.sup.2 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Patent expiration dates:
- November 21, 2015✓✓✓
- May 21, 2016✓
- November 21, 2015
Antibiotic compounds
Patent 5,652,233
Issued: July 29, 1997
Inventor(s): Betts; Michael John & Davies; Gareth Morse & Swain; Michael Lingard
Assignee(s): Zeneca Limited
The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 -alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(N-C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O)n- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to --NR.sup.3 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Patent expiration dates:
- February 2, 2013✓✓✓
- August 2, 2013✓
- February 2, 2013
Carbapenem antibiotic
Patent 5,952,323
Issued: September 14, 1999
Inventor(s): Zimmerman; Jeffrey A. & Williams; John M. & Bergquist; Paul A. & DiMichele; Lisa M. & DuBost; David C. & Kaufman; Michael J. & Sidler; Daniel R. & Hunke; William A.
Assignee(s): Merck & Co., Inc.
A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.Patent expiration dates:
- May 15, 2017✓
- November 15, 2017✓
- May 15, 2017
Antibiotic compounds
Patent 7,342,005
Issued: March 11, 2008
Inventor(s): Betts; Michael John & Davies; Gareth Morse & Swain; Michael Lingard
Assignee(s): AstraZeneca UK Limited
The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N—C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n—wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR3—; processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Patent expiration dates:
- February 2, 2013✓
- August 2, 2013✓
- February 2, 2013
See also...
- Invanz Consumer Information (Wolters Kluwer)
- Invanz Consumer Information (Cerner Multum)
- Invanz ADD-Vantage Consumer Information (Cerner Multum)
- Invanz Advanced Consumer Information (Micromedex)
- Invanz AHFS DI Monographs (ASHP)
- Ertapenem Consumer Information (Wolters Kluwer)
- Ertapenem Consumer Information (Cerner Multum)
- Ertapenem Injection Advanced Consumer Information (Micromedex)
- Ertapenem Sodium AHFS DI Monographs (ASHP)
No comments:
Post a Comment